<DOC>
	<DOCNO>NCT01190267</DOCNO>
	<brief_summary>This study design evaluate whether asenapine , approve United States Food Drug Administration ( US FDA ) acute treatment schizophrenia adult , generally safe well tolerated adolescent schizophrenia . This extension base study P05896 ( NCT01190254 ) , mean participant must complete participation 8-week base study order qualify extension study P05897 . Participants extension study receive open-label asenapine 26 week . Throughout study , observation make participant various time assess long-term safety , tolerability efficacy study treatment .</brief_summary>
	<brief_title>Flexible Dose , Long-term Safety Study Asenapine Treatment Schizophrenia Adolescents ( P05897 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Schizophrenia , Disorganized</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Each participant must 12 17 year age time entry study , however , participant 8week base study ( P05896 [ NCT01190254 ] ) reach 18 year age P05896 may enrol extension study provide inclusion/exclusion criterion meet . Must complete 8week efficacy safety trial ( P05896 [ NCT01190254 ] ) , accord investigator 's judgment , would benefit longterm treatment . Must demonstrate acceptable degree compliance trial medication , visit , requirement 8week trial ( P05896 [ NCT01190254 ] ) , opinion investigator . A female participant must pregnant must intention become pregnant trial . A participant must imminent risk selfharm harm others . A participant must currently involuntary inpatient commitment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>